Loading clinical trials...
Loading clinical trials...
A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study
Conditions
Interventions
STN1010904 ophthalmic suspension 0.03% BID
STN1010904 ophthalmic suspension 0.1% BID
+1 more
Locations
15
United States
Stein Eye Institution UCLA
Los Angeles, California, United States
Price Vision Group
Indianapolis, Indiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
Mayo Clinic
Rochester, Minnesota, United States
Tauber Eye Center
Kansas City, Missouri, United States
Comprehensive Eye Care, Ltd
Washington, Missouri, United States
Start Date
May 19, 2022
Primary Completion Date
May 26, 2025
Completion Date
May 26, 2025
Last Updated
July 15, 2025
NCT07024693
NCT04440280
NCT06966167
NCT06425666
NCT07217249
NCT05795699
Lead Sponsor
Santen Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions